DRUG
BRIGHT MINDS BIOSCIENCES INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Millennium Management | Q1 2025(8Q snapshot) | 5Q | $42 | $75 | +79% |
| D.E. Shaw | Q1 2026(8Q snapshot) | 1Q | $84 | $75 | -11% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q4 2025 | Q2 2026 | → $77 | +34% |
| Citadel Advisors 2× in & out | Q4 2025 | Q1 2026 | → $84 | +45% |
| Point72 Asset Management | Q1 2025 | Q1 2026 | → $84 | +101% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | → $81 | +38% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BRIGHT MINDS BIOSCIENCES INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 30, 2026 — the most recent Form 4 on file — not from today.
Fundamentals
XBRL · BRIGHT MINDS BIOSCIENCES INC.Not enough XBRL history to plot. BRIGHT MINDS BIOSCIENCES INC.hasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BRIGHT MINDS BIOSCIENCES INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KFORM 6-KJun 3, 2026
- 6-KFORM 6-KJun 2, 2026
- 6-KInterim disclosure (foreign)May 28, 2026
- 6-KFORM 6-KMay 20, 2026
- 6-KFORM 6-KFeb 13, 2026
- 6-KFORM 6-KJan 9, 2026
- 6-KFORM 6-KJan 9, 2026
- 6-KInterim disclosure (foreign)Jan 8, 2026
- 6-KFORM 6-KJan 7, 2026
- 6-KInterim disclosure (foreign)Jan 7, 2026
- 6-KInterim disclosure (foreign)Jan 6, 2026
- 6-KInterim disclosure (foreign)Jan 5, 2026
- 6-KFORM 6-KNov 17, 2025
- 6-KFORM 6-KNov 7, 2025
- 6-KFORM 6-KNov 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q1 2026 | open | $84 | $75 | -11% |
| Citadel Advisors | Q4 2025 | Q1 2026 | $58 | $84 | +45% |
| Two Sigma Investments | Q4 2025 | Q2 2026 | $58 | $77 | +34% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | $58 | $81 | +38% |
| Citadel Advisors | Q2 2025 | Q3 2025 | $32 | $43 | +31% |
| Millennium Management | Q1 2025 | open | $42 | $75 | +79% |
| Point72 Asset Management | Q1 2025 | Q1 2026 | $42 | $84 | +101% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.